PharmaTell

This week, we've shared details on some of the latest topics in BioPharma that caught our eye. Check out the AbbVie PD Approval, the Genentech and Lundbeck deals, and GSK's latest vaccine litigation. https://wix.to/KSH0R2S #pharmatell #strategicintel #CI #BioPharma #CurrentEvents #newblogpost

📊 New & Improved: The latest #biotech financing summary is here! Dive into the most recent trends, top funding rounds and key insights from August 2024. 🔗 Download the full report now: https://lnkd.in/eQkFBtTN

We've been catching up on the latest pharmaceutical news. This week, Amgen, Pfizer, and BMS caught our eye. What have you been tracking? #pharmaintel #eyesonpharma #pharmatell #currentevents #scd #schizophrenia #myastheniagravis #atopicdermatitis https://wix.to/cEwHZSO

We'll have Eyes on the Diabesity markets over the next few months to see how this decision impacts the companies and the patients.

Which BioPharma headlines caught your eye this month? We're still watching VC commentary, M&A activities, and FDA actions. https://wix.to/svRwnqH #EyesonPharmaBlog #BioPharmaNews #PharmaTell #StrategicHealthcareIntel #CompetitiveIntel

Our latest Eyes on Pharma blog post highlights some of the pharma news from August, including Yorvipath approval, mPox vaccine delivery, and a novel R&D platform for Oncology. Check it out here https://wix.to/uACt3NU #pharmatellstudio #eyesonpharma #pharmabizintel #strategichealthcareintel

Check out what caught our eye this week .... a few tidbits about Alzheimer's data, Oncology licensing, and patent cliffs .... all on our Eyes on Pharma blog. #eyesonphara #pharmatell #strategichealthcareintel

AbbVie’s #Humira has long dominated the biosimilar market, but recent data suggests a shift is imminent with a decrease in market share to 82%. Sandoz's #Hyrimoz, a key player, has seen significant gains under the Cordavis co-label, recording a surge in prescriptions after CVS Health Caremark's move to exclude branded Humira from commercial formularies in April. IQVIA data indicates that 82% of Humira biosimilar prescriptions were for Hyrimoz by the end of April, propelling Sandoz to a 6% sales growth in the first quarter. On the other hand, AbbVie's collaboration with Cordavis has resulted in a joint Humira formulation, capturing around 25% of the Cordavis-labelled products market, as per Samsung Bioepis' findings. Meanwhile, Boehringer Ingelheim's #Cyltezo, competing with Humira, faced challenges with only 1,487 prescriptions since its July 2023 launch, compared to Humira's 2.8 million prescriptions during the same period. The delayed uptake led to layoffs within Boehringer's customer-facing team, prompting a shift to a hybrid approach. As AbbVie prepares to transition focus to newer immunology medications like #Skyrizi and #Rinvoq to counter Humira's declining sales – dropping from a record $21.2 billion to $14.4 billion last year – the pharma landscape is evolving rapidly. Skyrizi's recent $2 billion quarterly sales almost matched Humira, which experienced a 40% sales decline in the first quarter. The pharmaceutical market is witnessing dynamic shifts and strategic maneuvers as key players navigate the evolving landscape. ------------- Stay tuned for more insights on PharmaTell Studio or read more on our blog: https://lnkd.in/gTtPWGMk

Competition in the inflammatory bowel disease drug development space is intensifying with recent acquisitions and advancements. Eli Lilly and Company's $3.2 billion buy-out of oral competitor Morphic Therapeutic is challenging Takeda's injectable #Entyvio. Morphic's MORF-057, currently in phase 2 development for Crohn’s disease and ulcerative colitis, aims to control intestinal inflammation by constraining α4β7, an integrin in white blood cells. Moreover, Ensho Therapeutics acquired a phase 2-ready oral α4β7 candidate from EA Pharma (Eisai Co., Ltd.’s GI subsidiary), adding to the competition faced by #Entyvio. While Morphic's stock surged initially, subsequent challenges led to a decrease, eventually enabling Lilly's premium offer. Data from Morphic's phase 2b trial in ulcerative colitis is expected in early 2025, shedding more light on the evolving landscape. Stay updated on PharmaTell Studio for more insights on these developments!

This week we've had Eyes On some of the competitive activities in BioPharma. Check out some of the M&A, New Clinical Data, Biosimilar growth and more. https://wix.to/rC6IQaW #newblogpost #PharmaCompetitiveIntel #BioPharmaNews #PharmaTell #EyesOnPharma